Publication:
SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)

Simple item page
dc.contributor.authorVaz-Salgado, Maria Angeles
dc.contributor.authorCigarral-Garcia, Belen
dc.contributor.authorFernandez-Perez, Isaura
dc.contributor.authorJimenez-Munarriz, Beatriz
dc.contributor.authorSampedro-Domarco, Paula
dc.contributor.authorHernandez-Gonzalez, Ainhoa
dc.contributor.authorVieito-Villar, Maria
dc.contributor.authorLuque-Caro, Raquel
dc.contributor.authorVillamayor-Delgado, Maria Luisa
dc.contributor.authorSepulveda-Sanchez, Juan Manuel
dc.contributor.authoraffiliation[Luque-Caro, R] Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria Ibs.Granada, Granada, Spain
dc.date.accessioned2025-11-03T09:33:30Z
dc.date.available2025-11-03T09:33:30Z
dc.date.issued2024-04-25
dc.description.abstractThe 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.
dc.description.versionYes
dc.identifier.citationVaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH, et al. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clin Transl Oncol. 2024 Nov;26(11):2856-2865
dc.identifier.doi10.1007/s12094-024-03456-x
dc.identifier.issn1699-3055
dc.identifier.pmcPMC11467015
dc.identifier.pmid38662171
dc.identifier.urihttps://hdl.handle.net/10668/28621
dc.issue.number11
dc.journal.titleClinical and Translational Oncology
dc.language.isoen
dc.page.number10
dc.publisherSpringer
dc.relation.publisherversionhttps://dx.doi.org/10.1007/s12094-024-03456-x
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAstrocytoma
dc.subjectGuideline
dc.subjectIDH mutation
dc.subjectLow-grade glioma
dc.subjectNeuro-oncology
dc.subjectOligodendroglioma
dc.subject.decsEnfoque GRADE
dc.subject.decsNeoplasias Encefálicas
dc.subject.decsManipulación Quiropráctica
dc.subject.decsQuimioterapia Combinada
dc.subject.meshOligodendroglioma
dc.subject.meshIsocitrate Dehydrogenase
dc.subject.meshAstrocytoma
dc.subject.meshMutation
dc.subject.meshWorld Health Organization
dc.titleSEOM-GEINO clinical guidelines for grade 2 gliomas (2023)
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number26
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Vaz-Salgado_SEOM-GEINO.pdf
Size:
720.05 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen de las Nieves
Instituto de Investigación Biosanitaria de Granada (ibsGRANADA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía